Finalist
Partner of Choice
by Arc Bio Communications for Astellas Pharma
Summary of work
Without scientific partnerships between large pharma companies and smaller biotechnology organisations, innovations that could fundamentally change how we treat, or even cure, diseases may never reach patients. To remain competitive, it is vital pharma companies attract the right scientific partners. As such, differentiation and clear communications on why you are an innovation partner of choice are business critical.
Astellas Medical & Development Communications and Arc Bio Communications built the Partner of Choice platform to position Astellas globally as the best scientific research and commercialisation partner in the company’s priority R&D areas. The approach focussed on reaching the right people in the life sciences innovator community in the right places and showcasing Astellas’ differentiated positioning and agile and entrepreneurial ways of working.
The programme led to a demonstrable increase in awareness of Astellas’ corporate and scientific reputation as a R&D and commercialisation partner among global life science innovators. This translated into increased engagement among strategically relevant partners and a significant rise in partnering requests. These requests could ultimately lead to new collaborations that transform the lives of patients in the future.
Judges’ comments
‘Partner of Choice’ is a comprehensive and well-executed programme with demonstrable results. The insights were excellent and there was a strong business rationale behind the objectives. The judges were particularly impressed by the programme’s outcomes, which showed a clear change in behaviour.
